These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9381528)

  • 1. Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts.
    Seino K; Kayagaki N; Tsukada N; Fukao K; Yagita H; Okumura K
    Transplantation; 1997 Oct; 64(7):1050-4. PubMed ID: 9381528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rejection of Fas ligand-expressing grafts.
    Seino K; Kayagaki N; Fukao K; Okumura K; Yagita H
    Transplant Proc; 1997; 29(1-2):1092-3. PubMed ID: 9123215
    [No Abstract]   [Full Text] [Related]  

  • 3. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
    Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
    J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.
    Allison J; Georgiou HM; Strasser A; Vaux DL
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3943-7. PubMed ID: 9108084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of CD95L expression on tumor rejection in mice.
    Igney FH; Behrens CK; Krammer PH
    Eur J Immunol; 2003 Oct; 33(10):2811-21. PubMed ID: 14515265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD95 ligand expression on corneal epithelium and endothelium influences the fates of orthotopic and heterotopic corneal allografts in mice.
    Osawa H; Maruyama K; Streilein JW
    Invest Ophthalmol Vis Sci; 2004 Jun; 45(6):1908-15. PubMed ID: 15161857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelium-deficient corneal allografts display immune privilege beneath the kidney capsule.
    Hori J; Joyce N; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):443-52. PubMed ID: 10670474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo.
    Nishimatsu H; Takeuchi T; Ueki T; Kajiwara T; Moriyama N; Ishida T; Li B; Kakizoe T; Kitamura T
    Cancer Immunol Immunother; 1999 Apr; 48(1):56-61. PubMed ID: 10235489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for CD95 ligand in preventing graft rejection.
    Bellgrau D; Gold D; Selawry H; Moore J; Franzusoff A; Duke RC
    Nature; 1995 Oct; 377(6550):630-2. PubMed ID: 7566174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune privilege and immunogenicity reside among different layers of the mouse cornea.
    Hori J; Joyce NC; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Sep; 41(10):3032-42. PubMed ID: 10967061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells.
    Shimizu M; Fontana A; Takeda Y; Yagita H; Yoshimoto T; Matsuzawa A
    J Immunol; 1999 Jun; 162(12):7350-7. PubMed ID: 10358186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
    Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
    Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
    Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
    J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
    Lau HT; Yu M; Fontana A; Stoeckert CJ
    Science; 1996 Jul; 273(5271):109-12. PubMed ID: 8658177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skin graft rejection elicited by beta 2-microglobulin as a minor transplantation antigen involves multiple effector pathways: role of Fas-Fas ligand interactions and Th2-dependent graft eosinophil infiltrates.
    Surquin M; Le Moine A; Flamand V; Nagy N; Rombaut K; Demoor FX; Stordeur P; Salmon I; Guéry JC; Goldman M; Abramowicz D
    J Immunol; 2002 Jul; 169(1):500-6. PubMed ID: 12077281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that retinal pigment epithelium functions as an immune-privileged tissue.
    Wenkel H; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Oct; 41(11):3467-73. PubMed ID: 11006240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marked mitigation of transplant vascular sclerosis in FasLgld (CD95L) mutant recipients. The role of alloantibodies in the development of chronic rejection.
    Subbotin V; Sun H; Aitouche A; Salam A; Valdivia LA; Fung JJ; Starzl TE; Rao AS
    Transplantation; 1999 May; 67(10):1295-300. PubMed ID: 10360580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional role of CD95 ligand in concanavalin A-induced intestinal intraepithelial lymphocyte cytotoxicity.
    Ghoreschi K; Muders M; Enders GA
    Immunology; 1998 Dec; 95(4):566-71. PubMed ID: 9893046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated rejection of Fas ligand-expressing heart grafts.
    Takeuchi T; Ueki T; Nishimatsu H; Kajiwara T; Ishida T; Jishage K; Ueda O; Suzuki H; Li B; Moriyama N; Kitamura T
    J Immunol; 1999 Jan; 162(1):518-22. PubMed ID: 9886428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the proinflammatory effects of Fas ligand (CD95L).
    Chen JJ; Sun Y; Nabel GJ
    Science; 1998 Nov; 282(5394):1714-7. PubMed ID: 9831564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.